Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- QURE
- Price
- 21.75
- Stock movement up
- +1.25 (6.10%)
- Company name
- Uniqure NV
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.35B
- Ent value
- 1.42B
- Price/Sales
- 86.02
- Price/Book
- 5.92
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 9.66%
- 1 year return (CAGR)
- 64.15%
- 3 year return (CAGR)
- -0.14%
- 5 year return (CAGR)
- -10.75%
- 10 year return (CAGR)
- 4.42%
Last updated: 2026-02-23
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
QURE does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 86.02 |
| Price to Book | 5.92 |
| EV to Sales | 89.99 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 62.29M |
| EPS (TTM) | -4.02 |
| FCF per share (TTM) | -2.63 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 15.75M |
| Gross profit (TTM) | 13.88M |
| Operating income (TTM) | -180.06M |
| Net income (TTM) | -235.15M |
| EPS (TTM) | -4.02 |
| EPS (1y forward) | -2.77 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 88.13% |
| Operating margin (TTM) | -1143.16% |
| Profit margin (TTM) | -1492.90% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 597.06M |
| Net receivables | 3.88M |
| Total current assets | 716.19M |
| Goodwill | 25.33M |
| Intangible assets | 74.14M |
| Property, plant and equipment | 71.98M |
| Total assets | 888.38M |
| Accounts payable | 6.23M |
| Short/Current long term debt | 66.16M |
| Total current liabilities | 100.63M |
| Total liabilities | 659.64M |
| Shareholder's equity | 228.75M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -153.24M |
| Capital expenditures (TTM) | 513.00K |
| Free cash flow (TTM) | -153.75M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -102.80% |
| Return on Assets | -26.47% |
| Return on Invested Capital | -82.64% |
| Cash Return on Invested Capital | -54.03% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 20.65 |
| Daily high | 22.23 |
| Daily low | 20.25 |
| Daily Volume | 1.90M |
| All-time high | 82.19 |
| 1y analyst estimate | 53.41 |
| Beta | 0.67 |
| EPS (TTM) | -4.02 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 2 Mar 2026 |
Downside potential
Loading...
Downside potential data
| QURE | S&P500 | |
| Current price drop from All-time high | -73.54% | -1.82% |
| Highest price drop | -95.40% | -56.47% |
| Date of highest drop | 8 Jul 2024 | 9 Mar 2009 |
| Avg drop from high | -56.08% | -10.84% |
| Avg time to new high | 61 days | 12 days |
| Max time to new high | 1673 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.35B
Marketcap category
Small-cap
Description
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Employees
209
Website
Investor relations
-
SEC filings
CEO
Matthew C. Kapusta
Country
USA
City
Amsterdam
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page